Aseptic API certification urges pharmaceutical companies to seize market voice

Guide: In recent years, the state has vigorously launched a series of industry policies and regulations and implemented, which has aroused the high attention of the pharmaceutical industryAmong them, the impact is more far-reaching is the new version of the drug GMP sterile certification, the policy will be to a large extent to purify the industry marketpYn
China's overproduction of API has always existed, mainly by the API industry low technical threshold, easy capacity replication, product sesame, and so on, resulting in the API industry can not long-term developmentNow, sterile API has passed the new version of the drug GMP certification, the API industry will certainly achieve good development in the futurepYn
Aseptic API certification to promote pharmaceutical companies to seize the market voicepYnpharmaceutical raw materials exports and domestic demand market integration trend is very obvious, because China has become the world's third largest pharmaceutical market, multinational pharmaceutical companies layout of China is acceleratingNow there are nearly 200 preparation enterprises of sterile products through the new version of the drug GMP certification, they are very much through the certification of sterile API, in the absence of suppliers, the first through the aseptic API certification API manufacturers will master a certain pricing powerpYn
At present, china's API is facing many adverse factorsChina's API in the international market position in the short term can not be replaced, vitamins, penicillin, citric acid, antibiotics, paracetamol and other bulk API drugs still have a certain price competitive advantagepYn
For the pharmaceutical industry API industry in the "12th Five-Year Plan" has become the key to innovation and transformation, also in the "12th Five-Year Plan" ushered in a new opportunity for the development of API industrypYn
At present, the process of the development of API industry is generally from the production of chemical raw materials, pharmaceutical intermediates and bulk API, after obtaining the production of API-related experience, enterprises gradually accumulated capital and technology, participate in the international competition of generic drugs, generic drugs, and finally to the production of patented drugsIn such a development process, enterprises through technological innovation, so that their own production technology is constantly updated, the industrial structure continues to transform and upgrade, the profits of enterprises will continue to improveThis invisibly adds to the confidence of enterprises to continue to innovate, forming a model of benign developmentAlthough the total export volume of API in China is growing, the phenomenon of overcapacity and product quality convergence in the industry still exists, and has become the biggest obstacle to the development of API in ChinaTo this end, industry experts suggest that API enterprises can develop new products and expand the industrial chain, mergers and acquisitions, production line upgrading and transformation of the three ways to transform and upgrade enterprises, grasp the opportunity of the development of APIWhether it is the implementation of the new version of the drug GMP certification, or chemical API consistency evaluation work, have a positive impact on the restructuring and upgrading of the pharmaceutical sub-industryThe implementation of these policies, enterprises on the one hand to face the increasing quality of drugs and more and more severe market competition, on the other hand, also test the insight of business leaders and the grasp of opportunitiesIn the face of such a policy environment, API enterprises only correctly understand and actively digest the policy, according to their own technology, capital and other practical conditions to do a good job of the direction of transformation positioning, to avoid blindly following the trend, in order to occupy the market opportunitypYnGuide: In recent years, the state has vigorously launched a series of industry policies and regulations and implemented, which has attracted the attention of the pharmaceutical industryAmong them, the impact is more far-reaching is the new version of the drug GMP sterile certification, the policy will be to a large extent to purify the industry marketpYn
　　China's overproduction of API has always existed, mainly by the API industry low technical threshold, easy capacity replication, product sesame, and so on, resulting in the API industry can not long-term development Now, sterile API has passed the new version of the drug GMP certification, the API industry will certainly achieve good development in the future pYn
　　Aseptic API certification to promote pharmaceutical companies to seize the market voice pYn pharmaceutical raw materials exports and domestic demand market integration trend is very obvious, because China has become the world's third largest pharmaceutical market, multinational pharmaceutical companies layout of China is accelerating Now there are nearly 200 preparation enterprises of sterile products through the new version of the drug GMP certification, they are very much through the certification of sterile API, in the absence of suppliers, the first through the aseptic API certification API manufacturers will master a certain pricing power pYn
　　At present, china's API is facing many adverse factors China's API in the international market position in the short term can not be replaced, vitamins, penicillin, citric acid, antibiotics, paracetamol and other bulk API drugs still have a certain price competitive advantage pYn
　　For the pharmaceutical industry API industry in the "12th Five-Year Plan" has become the key to innovation and transformation, also in the "12th Five-Year Plan" ushered in a new opportunity for the development of API industry pYn
　　At present, the process of the development of API industry is generally from the production of chemical raw materials, pharmaceutical intermediates and bulk API, after obtaining the production of API-related experience, enterprises gradually accumulated capital and technology, participate in the international competition of generic drugs, generic drugs, and finally to the production of patented drugs In such a development process, enterprises through technological innovation, so that their own production technology is constantly updated, the industrial structure continues to transform and upgrade, the profits of enterprises will continue to improve This invisibly adds to the confidence of enterprises to continue to innovate, forming a model of benign development Although the total export volume of API in China is growing, the phenomenon of overcapacity and product quality convergence in the industry still exists, and has become the biggest obstacle to the development of API in China To this end, industry experts suggest that API enterprises can develop new products and expand the industrial chain, mergers and acquisitions, production line upgrading and transformation of the three ways to transform and upgrade enterprises, grasp the opportunity of the development of API Whether it is the implementation of the new version of the drug GMP certification, or chemical API consistency evaluation work, have a positive impact on the restructuring and upgrading of the pharmaceutical sub-industry The implementation of these policies, enterprises on the one hand to face the increasing quality of drugs and more and more severe market competition, on the other hand, also test the insight of business leaders and the grasp of opportunities In the face of such a policy environment, API enterprises only correctly understand and actively digest the policy, according to their own technology, capital and other practical conditions to do a good job of the direction of transformation positioning, to avoid blindly following the trend, in order to occupy the market opportunity pYn